Baselines in Reproductive Disorders
Primary Purpose
Amenorrhea, Hypogonadotropic Hypogonadism, Kallmann's Syndrome
Status
Unknown status
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Frequent baseline blood sampling
Sponsored by
About this trial
This is an interventional diagnostic trial for Amenorrhea focused on measuring Hypothalamic Amenorrhea, Idiopathic hypogonadotropic hypogonadism, Acquired hypogonadotropic hypogonadism, Kallmann's Syndrome, Amenorrhea, Gonadotropin Releasing Hormone
Eligibility Criteria
Inclusion Criteria:
- Healthy women between the ages of 16-45 years
- Negative pregnancy test
- On no gonadal steroid preparations for at least 3 months, with the exception of the idiopathic hypogonadotropic hypogonadism (IHH) group, they should be off gonadal steroid for at least 4 weeks
The following test will be performed if they had not been done in the last 2 months
- Normal blood count
- Normal thyroid function test
Exclusion Criteria:
- Hemoglobin levels less than 11 gm/dL
- Positive pregnancy test
- Abnormal thyroid function
- Abnormal MRI (IHH)
Sites / Locations
- Massachusetts General HospitalRecruiting
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
1
Arm Description
Outcomes
Primary Outcome Measures
Number of luteinizing hormone (LH) and FAS (free alpha subunit) pulses
Secondary Outcome Measures
Amplitude of LH and FAS pulses
Inter-pulse interval for LH and FAS pulses
Full Information
NCT ID
NCT00456274
First Posted
April 2, 2007
Last Updated
July 31, 2014
Sponsor
Massachusetts General Hospital
Collaborators
National Institutes of Health (NIH)
1. Study Identification
Unique Protocol Identification Number
NCT00456274
Brief Title
Baselines in Reproductive Disorders
Official Title
Baselines in Reproductive Disorders
Study Type
Interventional
2. Study Status
Record Verification Date
July 2014
Overall Recruitment Status
Unknown status
Study Start Date
September 1999 (undefined)
Primary Completion Date
September 2020 (Anticipated)
Study Completion Date
September 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
National Institutes of Health (NIH)
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of the study is to explore the way in which gonadotropins (pituitary hormones) are released into the body. The knowledge acquired in this study will be used for the diagnosis and treatment of reproductive endocrine disorders.
We seek to investigate the baseline characteristics of the GnRH-induced gonadotropin pulsations of patients with the following diagnoses:
Hypothalamic Amenorrhea (HA)
Idiopathic hypogonadotropic hypogonadism (IHH)
Polycystic ovarian disease (PCOD)
Acquired hypogonadotropic hypogonadism (AHH)
Premature Ovarian Failure (POF)
**WE ARE CURRENTLY RECRUITING ONLY SUBJECTS WITH A DIAGNOSIS OF IHH.**
This has been an extremely productive and pivotal protocol in the studies of female reproductive physiology and pathophysiology and continues to be critical for defining the neuroendocrine abnormalities in patients with reproductive disorders. In some cases, it is also helpful in the planning of subsequent therapy if so desired.
It is important to note that minors have been included in this protocol, as many patients are extremely anxious to know more about their neuroendocrine disorder. With minors who would like to know if their disorder is correctable, this protocol may be followed up with administration of pulsatile gonadotropin-releasing hormone (GnRH).
Detailed Description
Normal reproductive cycles in women require the integrated function of the hypothalamus, pituitary and ovaries. The hypothalamic component of the reproductive system can be assessed directly in lower animal species by measurement of gonadotropin releasing hormone (GnRH) directly from pituitary portal blood and recording of multiunit activity from the median eminence of the hypothalamus, providing direct information about the physiology of GnRH secretion and the activity of the GnRH pulse generator. However, these techniques are not feasible in the human. In addition, measurement of GnRH levels in peripheral blood does not accurately reflect hypothalamic GnRH secretion. Thus, indirect methods must be used to gain insight into hypothalamic function in the human.
In the human, pulsatile luteinizing hormone (LH) secretion has been used as a mirror of hypothalamic GnRH secretion, citing comparative data from the rat, sheep, and non-human primate which indicate that pulses of LH are directly linked to antecedent pulses of GnRH. LH secretion thus provides an estimate of the underlying frequency of GnRH pulse generator activity provided that the assay is sufficiently precise, with a low coefficient of variation, and that blood sampling is frequent enough to accurately reflect the underlying frequency of episodic GnRH pulsatility. The use of pulsatile secretion of the free alpha subunit (FAS) of the gonadotropins has recently been proposed as an alternative and improved marker of GnRH secretion in the human due to a half-life of 15 minutes versus 20 to 40 minutes for LH. Despite the dual control of FAS by GnRH and thyroid releasing hormone (TRH), our studies have shown that the pulsatile component of FAS secretion is driven solely by GnRH in euthyroid subjects. Such studies have indicated:
the nearly complete concordance of pulses of FAS with those of LH in normal women, and in GnRH-deficient subjects undergoing GnRH replacement;
the absence of pulsatile secretion of FAS in GnRH-deficient subjects; and
the abolition of pulsatile FAS secretion in concert with that of LH following administration of a GnRH antagonist in normal and postmenopausal women.
We have proposed that abnormalities in the pulsatile secretion of GnRH underlie many reproductive abnormalities and that these may explain the clinical variability, which exists even within a given diagnostic category. In this protocol, we have sought to define the specific neuroendocrine profile in patients with amenorrhea or oligomenorrhea. In some patients, the results of these studies can then correlated with clinical outcomes of ovulation induction protocols and with genotype information. We have examined the spectrum of abnormal patterns of LH (and by inference GnRH) secretion in women with secondary hypogonadotropic hypogonadism. In 73 studies in 50 women, it has been determined that the most common neurosecretory defect is low frequency/low amplitude followed by normal frequency/normal amplitude, apulsatile, and low amplitude/normal frequency. Of patients studied on several occasions, 75% demonstrated at least 2 different patterns of LH secretion and 33% reverted at least once to a normal pattern of secretion. Study of the baseline patterns of LH secretion in patients with acquired GnRH deficiency/acquired hypothalamic hypogonadism (AHH) indicates that this group of patients has either an apulsatile pattern or a pattern of low amplitude LH pulses in comparison with normal women in the early follicular phase (matched for ovarian steroid levels). In these patients, the specific LH pattern does not predict response to pulsatile GnRH used for ovulation induction. FAS is apulsatile in the majority of patients with primary amenorrhea and absent LH pulses providing further support for the hypothesis that the pulsatile component of FAS secretion is primarily driven by GnRH in euthyroid patients despite the dual control of FAS by GnRH and TRH. As in men with presumed GnRH deficiency, occasional patients with absent LH pulses will have FAS pulses. These interesting patients are being further evaluated with respect to their pattern of TSH secretion and the bioactivity of their LH.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Amenorrhea, Hypogonadotropic Hypogonadism, Kallmann's Syndrome
Keywords
Hypothalamic Amenorrhea, Idiopathic hypogonadotropic hypogonadism, Acquired hypogonadotropic hypogonadism, Kallmann's Syndrome, Amenorrhea, Gonadotropin Releasing Hormone
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
180 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Other
Intervention Type
Procedure
Intervention Name(s)
Frequent baseline blood sampling
Intervention Description
3 ml of blood sampled every 10 minutes for a total of 8-12 hours
Primary Outcome Measure Information:
Title
Number of luteinizing hormone (LH) and FAS (free alpha subunit) pulses
Time Frame
8-12 hours
Secondary Outcome Measure Information:
Title
Amplitude of LH and FAS pulses
Time Frame
8-12 hours
Title
Inter-pulse interval for LH and FAS pulses
Time Frame
8-12 hours
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Healthy women between the ages of 16-45 years
Negative pregnancy test
On no gonadal steroid preparations for at least 3 months, with the exception of the idiopathic hypogonadotropic hypogonadism (IHH) group, they should be off gonadal steroid for at least 4 weeks
The following test will be performed if they had not been done in the last 2 months
Normal blood count
Normal thyroid function test
Exclusion Criteria:
Hemoglobin levels less than 11 gm/dL
Positive pregnancy test
Abnormal thyroid function
Abnormal MRI (IHH)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Natalie Shaw, MD
Phone
617-726-1895
Email
nshaw@partners.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Janet E Hall, M.D.
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
12. IPD Sharing Statement
Citations:
PubMed Identifier
8404603
Citation
Clarke IJ. Variable patterns of gonadotropin-releasing hormone secretion during the estrogen-induced luteinizing hormone surge in ovariectomized ewes. Endocrinology. 1993 Oct;133(4):1624-32. doi: 10.1210/endo.133.4.8404603.
Results Reference
background
PubMed Identifier
6504270
Citation
Wilson RC, Kesner JS, Kaufman JM, Uemura T, Akema T, Knobil E. Central electrophysiologic correlates of pulsatile luteinizing hormone secretion in the rhesus monkey. Neuroendocrinology. 1984 Sep;39(3):256-60. doi: 10.1159/000123988.
Results Reference
background
PubMed Identifier
332491
Citation
Nett TM, Adams TE. Further studies on the radioimmunoassay of gonadotropin-releasing hormone: effect of radioiodination, antiserum and unextracted serum on levels of immunoreactivity in serum. Endocrinology. 1977 Oct;101(4):1135-44. doi: 10.1210/endo-101-4-1135. No abstract available.
Results Reference
background
PubMed Identifier
7521353
Citation
Adams JM, Taylor AE, Schoenfeld DA, Crowley WF Jr, Hall JE. The midcycle gonadotropin surge in normal women occurs in the face of an unchanging gonadotropin-releasing hormone pulse frequency. J Clin Endocrinol Metab. 1994 Sep;79(3):858-64. doi: 10.1210/jcem.79.3.7521353.
Results Reference
background
Citation
Filicori M, Flamigni C, Crowley WF, Jr. The critical role of blood sampling frequency in the estimation of episodic luteinizing hormone secretion in normal women. In: Crowley Jr WF, Hofler JG (eds) The Episodic Secretion of Hormones. New York: Churchill Livingston.5-13, 1987.
Results Reference
background
PubMed Identifier
10843154
Citation
Hall JE, Lavoie HB, Marsh EE, Martin KA. Decrease in gonadotropin-releasing hormone (GnRH) pulse frequency with aging in postmenopausal women. J Clin Endocrinol Metab. 2000 May;85(5):1794-800. doi: 10.1210/jcem.85.5.6612.
Results Reference
background
PubMed Identifier
1693373
Citation
Whitcomb RW, O'Dea LS, Finkelstein JS, Heavern DM, Crowley WF Jr. Utility of free alpha-subunit as an alternative neuroendocrine marker of gonadotropin-releasing hormone (GnRH) stimulation of the gonadotroph in the human: evidence from normal and GnRH-deficient men. J Clin Endocrinol Metab. 1990 Jun;70(6):1654-61. doi: 10.1210/jcem-70-6-1654.
Results Reference
background
Citation
Crowley WF, Taylor AE, Martin KA, Whitcomb RW, Finkelstein JS, Hall JE. 1994 Use of the free alpha subunit (FAS) of glycoprotein secreting hormones as a surrogate marker of GnRH secretion in the human. In: Glycoprotein Hormones: Structure, Function and Clinical Implications. JW Lusbader, LD Puett, R Ruddon (eds), Serono Symposia, UAS pp. 253-63.
Results Reference
background
PubMed Identifier
10022439
Citation
Sharpless JL, Supko JG, Martin KA, Hall JE. Disappearance of endogenous luteinizing hormone is prolonged in postmenopausal women. J Clin Endocrinol Metab. 1999 Feb;84(2):688-94. doi: 10.1210/jcem.84.2.5433.
Results Reference
background
PubMed Identifier
747894
Citation
Kourides IA, Weintraub BD, Re RN, Ridgway EC, Maloof F. Thyroid hormone, oestrogen, and glucocorticoid effects on two different pituitary glycoprotein hormone alpha subunit pools. Clin Endocrinol (Oxf). 1978 Dec;9(6):535-42. doi: 10.1111/j.1365-2265.1978.tb01511.x. No abstract available.
Results Reference
background
PubMed Identifier
2105329
Citation
Hall JE, Whitcomb RW, Rivier JE, Vale WW, Crowley WF Jr. Differential regulation of luteinizing hormone, follicle-stimulating hormone, and free alpha-subunit secretion from the gonadotrope by gonadotropin-releasing hormone (GnRH): evidence from the use of two GnRH antagonists. J Clin Endocrinol Metab. 1990 Feb;70(2):328-35. doi: 10.1210/jcem-70-2-328.
Results Reference
background
PubMed Identifier
7962290
Citation
Hall JE, Martin KA, Whitney HA, Landy H, Crowley WF Jr. Potential for fertility with replacement of hypothalamic gonadotropin-releasing hormone in long term female survivors of cranial tumors. J Clin Endocrinol Metab. 1994 Oct;79(4):1166-72. doi: 10.1210/jcem.79.4.7962290.
Results Reference
background
PubMed Identifier
10372685
Citation
Perkins RB, Hall JE, Martin KA. Neuroendocrine abnormalities in hypothalamic amenorrhea: spectrum, stability, and response to neurotransmitter modulation. J Clin Endocrinol Metab. 1999 Jun;84(6):1905-11. doi: 10.1210/jcem.84.6.5823.
Results Reference
background
PubMed Identifier
10084591
Citation
Hayes FJ, McNicholl DJ, Schoenfeld D, Marsh EE, Hall JE. Free alpha-subunit is superior to luteinizing hormone as a marker of gonadotropin-releasing hormone despite desensitization at fast pulse frequencies. J Clin Endocrinol Metab. 1999 Mar;84(3):1028-36. doi: 10.1210/jcem.84.3.5579.
Results Reference
background
Links:
URL
http://www.massgeneral.org/reproendo/pages/reu_study_subject.htm
Description
MGH Reproductive Endocrine Research Studies
Learn more about this trial
Baselines in Reproductive Disorders
We'll reach out to this number within 24 hrs